Trial Profile

A Phase I/II Study of TheraT Vector(s) Expressing Human Papillomavirus 16 Positive (HPV 16+) Specific Antigens in Patients With HPV 16+ Confirmed Cancers

Status: Completed

Phase of Trial: Phase I/II

Latest Information Update: 09 Oct 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs HB 201 (Primary) ; HB 201 (Primary) ; HB 202 (Primary) ; Pembrolizumab (Primary)
Indications Anal cancer; Cancer; Cervical cancer; Gynaecological cancer; Head and neck cancer; Oropharyngeal cancer; Penile cancer; Solid tumours; Squamous cell cancer
Focus Adverse reactions; First in man; Proof of concept; Therapeutic Use
Sponsors Hookipa Pharma

Most Recent Events

15 Sep 2025 Status changed from active, no longer recruiting to completed.
14 Nov 2024 According to a HOOKIPA Pharma media release,Enrollment completed in the Phase 2 H200-001 study
14 Nov 2024 Status changed from recruiting to active, no longer recruiting.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com